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Introduction
Over the last few decades, epidemiologic studies have provided
clues linking infectious agents particularly viruses, to some types
of cancers. It is estimated that 1 5—20U of human malignancies have
an inlectious etiology with viruses accounting for approximately
I 0- 15’ of cases worldwide ‘‘. Some of the viruses and the malig
nancies associated with them include: human papillomavirus (HPV)
and cervical and other anogenital cancers: hepatitis B and C viruses
HBV. HCV I and hepatocellular carcinoma ([-ICC): Epstein—Barr
it-us EBV ) and nasopharvngeal carcinoma ( NPC . Burkitt’s N m—
phoma ( BL. and Hodgkin’s disease: human I-cell lvmphotrophic
virus t pc-I ( HTLV- 13 and adult T—ceIl leukemia and lvmphoma
(ATTE): human mmunodeticienc virus type— I HlV— I and lym—
phoma: and human herpesvirus t\ pe— ( Hl-IV—X and Kaposi’s sar
coma (KS. This review will attempt to summarize the current level
of kno ledge with respect to vimse.. c olactors. and the spectrum
of malignancies caused by or associated with them.
Human papillomavirus
HPV is one of the most common sexually transmitted infections
worldwide and the major cause of cer ical cancer . The molecular
detection ofthe virus in cervical lesions prompted the hypothesis and
subsequent studiesdemonstrating the association of HPV with penile
cancers as well as anal cancers in both males and females . HPV
is transmitted through sexual intercourse with an infected partner
with the risk of infection proportional to number of sexual partners
and encounters Cervical carcinoma is the second leading cancer
among v omen worldwide , In Ha au. as in the rest of the United
States, the overall incidence of cervical cancer has decreased os er
the 30 x ears due largel\ to the s mdespread use of Papanieoleau
screenitie. These early screenine progi has e led to detection ot
cervical precancerous leNions with suhsequeut increase in appropri
ate ii icd ical inters entions or [ol lo —up. I lowe \ er. the niorbidit and
morialit from cervical cancer continues io he a major health issue
among omen in resource-li mi ted areas such as Al rica.
Ut the approximately lOll dmlferent oenotvpcs of [WV. approxi—
mateR 3() inlect the eeniials and at least li of these are considered
to he omicogenic or porentiall\ oncogcnic. including HP\ l( and
I . the t\ p most frequentl\ found in cers ical cancers
Hepatitis B and C
Both HBV and [[CV viruses arc majorcauses of HCC, which account
for over 80U of primary liver cancers worldwide ‘. Worldwide.
HCC ranks as the fourth most common cancer and the third most
frequent cause of cancer death . The incidence of HCC varies
geographically with higher rates in sub-Saharan Africa. China, and
southeast Asia where liver cancers are primarily caused by HBV
In the UnitedStates, as well as Japan and Europe, HCC rates are much
loss er and are predominantly caused by HCV °. Although relatively
rare in North America. the rates of HCC’ in the United States have
increased 70- with the rates in men being 2 to 4 times higher than
in women . In Hawaii. the incidence of HCC is higher compared
to the test of the U.S. and this differential is more apparent in men
than in women (Figure I ). This is likely due to the high proportion
ot incli iduals immigrating trom high—incidence areas.
H B V is transmitted through i niected blood or blood products
ia contaminated needles or blood transfusions. HBV can also be
acquired sexually through exposure to infected body fluids. HCV
is primarily transmitted through contaminated needles or blood
transfusions. In the U.S.. before widespread screening of blood
products was initiated, [[CV was primarily transmitted by transfusion
of contaminated blood products l Today in the U.S., it is usually
acquired via needle sharing sitli intravenous drugs .
Epstein-Barr virus
FBV is a ubiquitous infection worldwide transmitted orally through
saliva and breast milk. EBV is associated with undifferentiated mm
sophar ngeal carcinoma . BL - 1-lodgkin’s disease . and other
N mphoid malignancies.
PC incidence has a ss ide geographic and ethnic variation. xa—
sopharvngeal carcinoma is coni mon in si mthern China and among
Chinese in Singapore and Hong Kon. as well as in parts of south
casi Asia. where men are inosi at fected . In Ha.s au. rates of N PC
are higher airmong Chinese than ‘ther ethnic eroups. BL is endemic
in tropical areas of Africa and generally iare in other parts of the
odd. This childhood cancer is characterized hs tumors in oh ing
the as s. maxillaries. and/or ahdomen . Approximatel\ a third of
Hodgkin’s disease cases ha e LB\ or EB\ gene producis detected
in RLd StLi nhsrg Ils Ilk ilk of Hodgkin s disy is L
HANA MsrDvAL ./* APSS I,. 2(5)5
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ncidence rates are per 1OU000 and are age adjusted to the 2000 US. standard population.
Source: Hawaii Tumor Registry, Cancer Research Center ot Hawaii: Surveillance, Epidemiology, and End Results ISEER) Program, National Cancer Institute
in young adults followed second larger peak in elderly adults
This age pattern may reflect different age-related responses to
EBV-infection.
Human T-cell lymphotrophic virus type I
The retrovirus, HTLV- I, is the cause of ATLL 2, HTLV- 1 is
transmitted through breastfeeding, sexual intercourse, intravenous
drug use, and blood transfusions. HTLV-l prevalence exhibits
geographic and ethnic variation .Atleast lOft of the adult popula
tion is infected in endemic areas such southern Japan. sub-Saharan
Africa, the Caribbean, parts of South America. Papua New Guinea,
and some areas of the Middle East . In Japan and other endemic
areas, the risk of ATLL increases dramatically between ages 40 and
65 after which risk declines steadily 22,
Human immunodeficiency virus type-I
Shortly afterthe HI-i epidemic was recognized. malignancies were
shown to be associated with the virus, either directly or indirectly
through the immune dysfunction caused by HIV-l 224.Although
a direct cause and effect has yet to link DIV-I to malignancies, its
impact on the immune regulatory system likely plays a role in B-cell
lymphomas and HIV- I-associated cancers 27,26
Human herpesvirus type-8
HHV-8. also known as Kaposi’s sarcoma herpesvirus (KSHV),
may be causally related to KS, primary effusion lymphoma and
multicentric Castleman’s disease 27 2< While initially’ linked only
to HIV— I—associated KS. other epidemiological forms of KS as
well as other lymphoid malignancies have now been tied to HHV
8!KSE-lV,
Mechanisms and Epidemiology of Viral Onco
genesis
Viruses that are associated with cancers have important similarities
and differences, particularly with respect to mechanisms ofoncogen
HPV N 1 sm ill DNA irus ss hich lusc m ihgn mt trans
formation though inactivation of human tumor suppressor proteins.
p53 and retinoblastoma, by viral proteins, resulting in disregulation
of cell growth mechanisms and genetic instability. HPV is able to
integrate into the host’s DNA and thus contribute to cervical carci
noma . HBV and HCV cause malignancy through indirect means.
Chronic HBV and DCV liver infections result in inflammation.
cell death, tissue scarring, and, finally. clonal regeneration of tis
sue. This cycle disrupts normal cell growth and increases the risk
of malignant transformation . HBV. a partially double-stranded
DNA virus, is phylogenetically unrelated to HCV, an RNA virus.
HBV uses an RNA intermediate for its replication and, like HPV,
is able to integrate into the host genome, which may contribute
directly to carcinogenesis . As an RNA virus, DCV is unable to
integrate into genomic DNA and it is not completely clear how the
virus establishes a chronic infection. EBV, a large. double-stranded
DNA virus, integrates into the host genome during the lytic phase
of infection. Following primary infection, EBV establishes latent
infection in B cells establishing a lifelong reservoir for the virus
. Latently infected cells can subsequently undergo uncontrolled
proliferation leading to malignant transformation.
Presence of oncogenic viruses is common in the general popula
tion hut only a limited proportion of infected individual develop
malignancies. Forexample, HPV is prevalent in approximately 25ff
of all sexually active women hut most [IPV—infected women remain
asymptomatic and relatively few progress into cervical cancer . In
areas of highest HBV prevalence (China and Africa), up to 15%
of the population are chronic HBV carriers, hut only’ 25% of those
infected develop DCC . In the U.S. where HCV-associated HCC
is the predominant type, overall prevalence of DCV is less than 2%
After initial infection, approximately 80% of individuals develop
chronic DCV infection and, of these carriers. 1 -5ff progress to
HCC 20-30 years later EBV is a ubiquitous infection with 80%
of individuals worldwide infected by the age of 30 Despite its
high prevalence, with the exception of endemic areas of tropical
Africa EB\ associated BI N rd itiscI rir,.
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The incongruentrates of infection and malignancies underscore the
potential role of cofactors in virus-associated cancers. For cervical
cancers, co-factors such as parity, smoking. and concurrent infection
with other sexually transmitted pathogens ma plavarolc . Risk
of HBV and FIC V—associated HCC may he influenced by cofactors
stich as 1 i er cirrhosis, alcohol consumption. cigarette smoking. and
tor. l-IBV. exposure to atlatoxin fungus—contaminated food products
\PC is strongk associated with the consumption of salted
fish. possihl due to high nitrosainine content: as well as a potential
genetic predisposition N, Innate immune responses to EBV ma\
also influence NPC development a ith individuals developing leA
antibodies to EBV having an increased risk for NPC . In tropical
Africa. de eloprnent of endemic BL ma\ be exacerbated by chronic
infection with Plasrnothoin /a/cl’pirnoi. malaria), which suppresses
cell-mediated immunity and consequently increases risk of BL
BI also involves the activation of the c-myc oncogene resulting
from a specific chromosomal translocation . In addition to its role
as a cancer-associated virus, HIV- I may also be considered a cofac
tor . EBV and HI-IV-8/KSHV may increase their risk in causing
lymphoma and KS, respectively, in WV-I-infected individuals.
Cancer-associated viruses commonly have the ability to develop
persistent or chronic infections. It is this chronicity that permits
malignant progression as most cancers take decades to develop.
For some oncogenic viruses, the age of infection is critical to the
establishmentof chronic infection and subsequent malignant progres
sion. Infection with EBV during infancy and very early childhood
increases the risk of Bk ‘. This is consistent with the high rates of
BL in areas of tropical sub-Saharan African where primary EBV
infections usuall occur before age 2. Infection with EBV during
later childhood increases the risk of NPC “. High rates of NPC
are observed in southern China and parts of southeast Asia where
pri mars infection occurs among school—aged children pri man lv
through young household or community contacts “. Ver early
injection with HBV increases the risk of HCC. particularl\ among
infants from HBV-infected mothers who are HBV e antigen-posi
tive carriers or horizontal transmission from recently infected voting
household members or playmates ‘. Nearly all I-IBV-infections
acquired at an early age become chronic and are likely to progress
to HCC. In contrast. HBV acquired during adulthood rarely becomes
chronic and, consequently, rarely progresses into HCC . Most HPV
infections are transient, particularly in young women, and resolve
within a few months . However, a small number of HPV—infected
women develop persistent infections and it is these women who are
at greatest i’isk for developing cer\ cal cancer
Future Directions
As in other infectious-related diseases, the impact of vaccines has
could dramaticatlv influence the inc deuce 01 virus—associated
malignancies. For instance. HB\ vaccine. et’tective against all HBV
gcflot\ pes. could suhstantiall reduce the rate of [ICC worldwide. A
vaccine against HCV could potentiall ha e the sanie effect. a could
other measures such screening blood products. Recent development
ci a proph lactic 1-IPV vaccine, which has shown ereat promise in
carl trials, has the potential to offer pnimar\ prevention ot HP\ in
fection \\ ith subsequent reductions in cer ical cancer. IJnfortnnatel
no HTLV- I or HIV- I vaccine is ax amIable vet. Primary pre\ ention
ol’ I ITLV— I and HIV- I has been addressed through education.
dccrcase isk of e posure. and sLreenin of blood products. Futur
successes in prexenting irus associated malignancies will likelx
benefit from further adxances in prex cut Iti’ie measures. includiite
accine deselopment. appiopriate screLning. and elimination of
acute or chronic infection.
For more information about the Cancer Research ( enter of Haxn ai i
please isit out w ebsite at w w .crch.org.
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